[go: up one dir, main page]

EP1651239A4 - Administration intravasculaire d'acides nucleiques non viraux - Google Patents

Administration intravasculaire d'acides nucleiques non viraux

Info

Publication number
EP1651239A4
EP1651239A4 EP03814414A EP03814414A EP1651239A4 EP 1651239 A4 EP1651239 A4 EP 1651239A4 EP 03814414 A EP03814414 A EP 03814414A EP 03814414 A EP03814414 A EP 03814414A EP 1651239 A4 EP1651239 A4 EP 1651239A4
Authority
EP
European Patent Office
Prior art keywords
cell
nucleic acid
viral nucleic
intravascular delivery
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03814414A
Other languages
German (de)
English (en)
Other versions
EP1651239A1 (fr
Inventor
Jon A Wolff
James E Hagstrom
Vladimir G Budker
David B Rozema
Sean D Monahan
Paul M Slattum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Madison Inc
Original Assignee
Mirus Bio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/600,290 external-priority patent/US7148205B2/en
Priority claimed from US10/600,098 external-priority patent/US20030216347A1/en
Application filed by Mirus Bio Corp filed Critical Mirus Bio Corp
Publication of EP1651239A1 publication Critical patent/EP1651239A1/fr
Publication of EP1651239A4 publication Critical patent/EP1651239A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à un procédé permettant de transfecter un matériel génétique dans une cellule de mammifère, afin de modifier les propriétés endogènes de ladite cellule. Le procédé selon l'invention consiste à mettre au point un polynucléotide destiné à être transfecté, puis à introduire le polynucléotide dans un vaisseau sanguin de mammifère, tel qu'une veine ou une artère caudale. Avant, après ou pendant l'introduction, l'on augmente la perméabilité du vaisseau, ce qui permet d'administrer le matériel génétique à la cellule parenchymateuse, et de modifier ainsi les propriétés endogènes de ladite cellule.
EP03814414A 2003-06-20 2003-07-22 Administration intravasculaire d'acides nucleiques non viraux Withdrawn EP1651239A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/600,290 US7148205B2 (en) 1995-12-13 2003-06-20 Intravascular delivery of non-viral nucleic acid
US10/600,098 US20030216347A1 (en) 1999-02-26 2003-06-20 Intravascular delivery of non-viral nucleic acid
PCT/US2003/022817 WO2005004879A1 (fr) 2003-06-20 2003-07-22 Administration intravasculaire d'acides nucleiques non viraux

Publications (2)

Publication Number Publication Date
EP1651239A1 EP1651239A1 (fr) 2006-05-03
EP1651239A4 true EP1651239A4 (fr) 2006-12-20

Family

ID=34068491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03814414A Withdrawn EP1651239A4 (fr) 2003-06-20 2003-07-22 Administration intravasculaire d'acides nucleiques non viraux

Country Status (2)

Country Link
EP (1) EP1651239A4 (fr)
WO (1) WO2005004879A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050617A1 (fr) * 1999-02-26 2000-08-31 Mirus Corporation Administration intravasculaire d'acide nucleique non viral
US20010004636A1 (en) * 1995-12-13 2001-06-21 Sean D. Monahan Intravascular delivery of non-viral nucleic acid
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020137707A1 (en) * 1997-12-30 2002-09-26 Monahan Sean D. Intravascular delivery of non-viral nucleic acid
US20030092180A1 (en) * 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
WO2003080794A2 (fr) * 2001-08-27 2003-10-02 Mirus Corporation Inhibition de la fonction d'arn par delivrance d'inhibiteurs dans des cellules animales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658892A (en) * 1993-01-15 1997-08-19 The General Hospital Corporation Compound delivery using high-pressure impulse transients
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
US6177403B1 (en) * 1996-10-21 2001-01-23 The Trustees Of The University Of Pennsylvania Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US20010004636A1 (en) * 1995-12-13 2001-06-21 Sean D. Monahan Intravascular delivery of non-viral nucleic acid
US20020137707A1 (en) * 1997-12-30 2002-09-26 Monahan Sean D. Intravascular delivery of non-viral nucleic acid
WO2000050617A1 (fr) * 1999-02-26 2000-08-31 Mirus Corporation Administration intravasculaire d'acide nucleique non viral
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20030092180A1 (en) * 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
WO2003080794A2 (fr) * 2001-08-27 2003-10-02 Mirus Corporation Inhibition de la fonction d'arn par delivrance d'inhibiteurs dans des cellules animales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUDKER V ET AL: "THE EFFICIENT EXPRESSION OF INTRAVASCULARLY DELIVERED DNA IN RAT MUSCLE", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 5, no. 2, February 1998 (1998-02-01), pages 272 - 276, XP002921644, ISSN: 0969-7128 *
GLASSPOOL-MALONE JILL ET AL: "Marked enhancement of direct respiratory tissue transfection by aurintricarboxylic acid", 1 July 1999, HUMAN GENE THERAPY, VOL. 10, NR. 10, PAGE(S) 1703-1713, ISSN: 1043-0342, XP002404913 *
See also references of WO2005004879A1 *

Also Published As

Publication number Publication date
EP1651239A1 (fr) 2006-05-03
WO2005004879A1 (fr) 2005-01-20

Similar Documents

Publication Publication Date Title
EP1667728A4 (fr) Delivrance intravasculaire d'un acide nucleique non viral
AU2020259548B2 (en) Methods and compositions for editing RNAs
WO2005007811A3 (fr) Injection de cellules et de fluides derives de ma moelle osseuse pour angiogenese
WO2002024232A3 (fr) Nouvelles formulations ameliorees de vecteurs de polyethyleneimine/adn aux fins d'un apport genique in vitro
WO2006096815A3 (fr) Promoteur htmc et vecteurs destines a l'expression hautement efficace et selective pour une tumeur de genes therapeutiques contre le cancer
US12139707B2 (en) Stabilized CRISPR complexes
CN112041436A (zh) 雷帕霉素抗性细胞
WO2002030470A8 (fr) Procedes et compositions permettant la diffusion d'acide nucleique
WO2007015771A3 (fr) Composition et procede pour introduction de sequences d'interference d'arn dans des cellules et tissus cibles
WO2005073384A3 (fr) Signal de polyadenylation de neuropiline-1 primaire humaine soluble et ses utilisations
EP2184609A3 (fr) Compositions et méthodes pour traiter le cancer du poumon
EP1651239A4 (fr) Administration intravasculaire d'acides nucleiques non viraux
EP3585443B1 (fr) Régulation d'expression génique par modulation médiée par aptamère de l'accessibilité de signaux de polyadénylation
EP1020529A3 (fr) Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales
WO2008070273A3 (fr) Procédés d'expression de la protéine de minéralisation lim
EP1246649A4 (fr) Administration intravasculaire d'acide nucleique
WO2005112997A3 (fr) Composition et procede pour l'introduction de sequences d'interference a orientation adn ou arn direct dans des cellules et tissus cibles
JP6296434B2 (ja) 機能性核酸分子の構築法
WO2000052164A3 (fr) Nouvelles molecules du canal potassique et leur utilisation
WO1997015668A3 (fr) Procedes et compositions comprenant glut-2 et des chimeres de glut-2
WO2005074357A3 (fr) Regulation de l'expression genetique dans des cellules vegetales
WO2007124452A3 (fr) PROCÉDÉS POUR L'EXPRESSION DE MULTIPLES ARNsi ET ARNsh À PARTIR D'UN VECTEUR UNIQUE
WO2023147479A1 (fr) Complexes crispr-cas conjugués
WO2008127486A3 (fr) Capsides à arndb capables de réplication et leurs utilisations
KR101670254B1 (ko) 목적 유전자의 발현 억제 특이성이 증가된 siRNA 분자

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIRUS BIO CORPORATION

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101AFI20061031BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20061120

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROZEMA, DAVID, B.

Inventor name: WOLFF, JON, A.

Inventor name: SLATTUM, PAUL, M.

Inventor name: MONAHAN, SEAN, D.

Inventor name: BUDKER, VLADIMIR, G.

Inventor name: HAGSTROM, JAMES, E.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAGSTROM, JAMES, E.

Inventor name: ROZEMA, DAVID, B.

Inventor name: MONAHAN, SEAN, D.

Inventor name: WOLFF, JON, A.

Inventor name: BUDKER, VLADIMIR, G.

Inventor name: SLATTUM, PAUL, M.

17Q First examination report despatched

Effective date: 20070620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080103